Loading data for MSLE — first visit, this takes a few seconds.

提醒

Satellos Bioscience Inc. (MSLE)

NasdaqGM: MSLE · 即時價格 · USD

8.66

-0.95 (-9.89%)

收盤價： Aug 28, 2026, 8:00 PM

8.83

+1.96%

盤後: 5:51 PM

股價、關鍵數字和最新消息，都在這一頁。

-9.89% (1D)

無可用資料

買價	10.2
市值	183.73M
營收 (ttm)	n/a
淨利（ttm）	-34.61M
	1.17
	-1.95
	n/a
	-3.17
P/B (ttm)	3.01
P/S (ttm)	n/a
財報日期	Nov 12, 2026

賣價	10.15
成交量	17,953
20 日平均成交量	54,701
開盤價	9.54
前收盤價	9.61
當日區間	8.66 - 9.54
52 週範圍	5.30 - 13.39
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 MSLE

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenn...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Aug 3, 2012

員工 18

證券交易所 NasdaqGM

股票代號 MSLE

網站 https://satellos.com

完整的公司簡介

財務表現

Satellos Bioscience 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -24.87M，較前期增加 20.54%。

財務報表

財報驚奇

Satellos Bioscience 已於 Aug 13, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.56 超出預期 0.01, 年增 -27.27% 下滑.

下次財報發布

Satellos Bioscience Inc. 的下次財報預計於 Nov 12, 2026, 盤中。
分析師預估營收 ... 升級

新聞動態

1 月前 · MarketBeat

Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update

Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne mus...

1 月前 · Benzinga

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

Recently listed, Satellos Bioscience Inc. (NASDAQ:MSLE) on Wednesday reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD) The data showed ...

1 月前 · MT Newswires

Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients

Satellos Bioscience (MSLE) said Wednesday six-month interim data from a phase 2 trial showed that it

3 月前 · Simply Wall St.

We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

4 月前 · 24/7 Wall St.

Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More

Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline...

第 1 頁，共 2 頁

Satellos Bioscience Inc. (MSLE)